|
6.
|
Description of content: Proposed
rule - The Environmental Protection Agency (EPA) is proposing to address the
unreasonable risk of injury to human health presented by carbon tetrachloride
(CTC) under its conditions of use as documented in EPA's
2020 Risk Evaluation for Carbon Tetrachloride and 2022 Revised Unreasonable Risk
Determination for Carbon Tetrachloride pursuant to the Toxic
Substances Control Act (TSCA). CTC is a volatile, organic compound that is primarily used as a
feedstock (i.e., processed as a reactant) in the making of products such as
refrigerants, aerosol propellants, and foam-blowing agents. TSCA requires
that EPA address by rule any unreasonable risk of injury to health or the
environment identified in a TSCA risk evaluation and apply requirements to
the extent necessary so that the chemical no longer presents unreasonable
risk. EPA determined that CTC presents an unreasonable risk of injury to
health due to cancer from chronic inhalation and dermal exposures and liver
toxicity from chronic inhalation, chronic dermal, and acute dermal exposures
in the workplace. To address the identified unreasonable risk, EPA is
proposing under TSCA to establish workplace safety requirements for most
conditions of use, including the condition of use related to the making of
low Global Warming Potential (GWP) hydrofluoroolefins (HFOs), prohibit the
manufacture (including import), processing, distribution in commerce, and
industrial/commercial use of CTC for conditions of use where information
indicates use of CTC has already been phased out, and establish recordkeeping
and downstream notification requirements. The use of CTC in low GWP HFOs is
particularly important in the Agency's
efforts to support
the American Innovation and Manufacturing Act of 2020 (AIM Act) and the Kigali
Amendment to the Montreal Protocol on Substances that Deplete the Ozone Layer, which was ratified on 26 October 2022.
|